Trial Profile
Emtricitabine and tenofovir alafenamide (FTC/TAF) fixed dose combination in patients with Human Immunodeficiency Virus (HIV) infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2017
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2017 New trial record